Earnings Call Intelligence Subscribe
Home › Call Sheets › REGN › Q4'25
Call sheet · Q4'25

Regeneron Pharmaceuticals (REGN)

Q4'25 earnings call · held January 30, 2026 · compared with the Q3'25 call · management-credibility review
8/12
Disclosure score
-
Financial quality
Bottom line
The sleeper story is REGN's massive U.S. manufacturing investment playing perfectly into Trump administration priorities while competitors scramble - this could be a major competitive moat if government contracts follow. The obvious headline is EYLEA HD's strong growth, but the real story is they're betting everything on prefilled syringe approval in April to fully unlock potential before biosimilars devastate the franchise. The binding constraint is manufacturing execution - they've got the science but keep getting tripped up by third-party fillers and FDA inspections. Most revealing quote: Schleifer's 'we remain optimistic about striking a deal with the administration' suggests serious high-level government negotiations underway. My view changes if the prefilled syringe gets another CRL or if Libtayo's melanoma combo data disappoints - either would signal execution problems in their two biggest 2026 catalysts.

The 30-second version

  • SLEEPER STORY: U.S. manufacturing becomes strategic differentiator as $7B+ investment plays into geopolitical tailwinds
  • EYLEA biosimilar cliff accelerates in 2026, but HD prefilled syringe approval becomes make-or-break catalyst
  • Pipeline promises getting vaguer - 18 Phase III studies is impressive scale but lacks the surgical precision of prior commitments

What changed this quarter

MetricQ3'25Q4'25Change
Total Revenue$3.8B (+1% YoY)$3.9B (+3% YoY)Acceleration to 3% growth
Dupixent Global Sales$4.9B (+26% YoY)$4.9B (+32% YoY)+600 bps acceleration
EYLEA HD US Sales$431M (+10% YoY)$506M (+66% YoY)Explosive +5600 bps acceleration
Libtayo Global Sales$365M (+24% YoY)$425M (+13% YoY)-1100 bps deceleration
Diluted EPS$11.83$11.44-3.3% sequential decline
R&D Expense$1.3B$1.3BFlat despite 'expanding late stage pipeline'
Free Cash Flow (9M)$3.2B (9M 2025)$4.1B (FY 2025)Strong full-year delivery
Share Repurchases$2.8B (9M)$3.4B (FY)Aggressive capital return
Sanofi Development Balance$900M (Q3)Under $600M (Q4)-$300M quarterly burn rate
Cash & Marketable Securities$16B (Q3)$16.2B (Q4)Stable war chest

Accountability tracked

8 new promises made5 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full REGN Q4'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.